Sourour Idoudi

Ms. Sourour Idoudi

Qatar University, Doha, Qatar
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2023 in Journal of Nanotheranostics
Verified
Journal Article
Open access
PDF file
SISourour Idoudi
Sourour Idoudi
RIRoua Ismail
Roua Ismail
OROusama Rachid
Ousama Rachid
AEAbdelbary Elhissi
Abdelbary Elhissi
AAAlaaldin M Alkilany
Alaaldin M Alkilany
Gold nanoparticles (AuNP) have received a growing attention due to their fascinating physiochemical properties and promising range of biomedical applications including sensing, diagnosis and cancer photothermal ablation. AuNP enjoy brilliant optical properties and ability to convert light into local heat and function as a “nanoheaters” to fight cancer. However, AuNP are poor drug delivery systems as they do not have reservoirs or matrices to achieve an acceptable drug loading efficiency. On the other end, liposome-based nanocarriers do not exhibit such optical properties but are excellent platform for drug loading and they have been proven clinically with a true presence in the market since the FDA approved Doxil® in 1995. Combining the brilliant optical and photothermal properties of AuNP with the excellent drug loading capability of liposome should yield nanocomposites that enjoy the features of both modalities and enable the development of novel and smart drug delivery systems. Therefore, this review discusses the up-to date research on the AuNP-liposome nanocomposites and the current available approaches and protocols for their preparation and characterization. Finally, the biomedical applications of AuNP-liposome nanocomposites and proposed future directions in this field are discussed.

29 October 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SISourour Idoudi
Sourour Idoudi
HKHadeel Kheraldine
Hadeel Kheraldine
GAGazala Anamangadan
Gazala Anamangadan
SSSumayyah Saeed
Sumayyah Saeed
FAFareed Ahmad
Fareed Ahmad
AAAlaaldin M Alkilany
Alaaldin M Alkilany
Melanoma is the most aggressive subtype of skin cancer with limited treatment options due to toxicity and therapy resistance. This study investigates the anticancer potential of ketamine (KET), an anesthetic recently reported to have anticancer effects, in combination with dodecyl maltoside (DDM), a permeation enhancer that may improve drug delivery. The effects of KET and KET + DDM were evaluated in MDA-MB-435 melanoma cells via cell viability, IC₅₀ determination, apoptosis, cell cycle distribution, migration, colony formation, and protein expression studies. Normal fibroblasts were used to assess safety. Compared to KET alone, the KET + DDM combination significantly reduced the viability of MDA-MB-435 cells while maintaining safety in NFBs. This combination also promoted significant apoptosis, induced cell cycle arrest at the G2/M phase, and inhibited migration and colony formation, while maintaining safety in normal fibroblasts Western blot analysis revealed upregulation of Bax and downregulation of Bcl-xl, p53, and Caspase-8, suggesting a mechanism of apoptosis. These findings demonstrate that KET, particularly when combined with DDM, holds promise as a potential topical therapeutic strategy against melanoma. It is suggested that KET + DDM might promote apoptosis through alternative, caspase-independent pathways, underscoring the need for further mechanistic studies. Further in vivo studies are warranted to validate its clinical applicability.

22 November 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SISourour Idoudi
Sourour Idoudi
ASAlaaeldin Saleh
Alaaeldin Saleh
MAMOHAMMED AKKBIK
MOHAMMED AKKBIK
LALeena Amine
Leena Amine
PAProf. Khalid Alansari
Prof. Khalid Alansari
AAAlaaldin M Alkilany
Alaaldin M Alkilany
Background: Ketamine HCl, an FDA-approved therapeutic, is administered through various routes, including intranasal delivery. Administering an adequate therapeutic dose of intranasal ketamine HCl is challenging due to the limited volume that can be delivered intranasally given the current commercially available concentrations. Objectives: This study investigates solubilizing strategies to enhance the aqueous solubility of ketamine HCl for intranasal administration. Methods: We assessed the solubility profile of ketamine HCl by evaluating factors such as pH, co-solvents, and surfactants. Additionally, we developed and validated a UV-Vis spectroscopy method for ketamine HCl analysis. Results: Our solubility screening in various organic co-solvents revealed the following order of effectiveness in enhancing solubility: methanol > water > propylene glycol > ethanol > dimethyl sulfoxide (DMSO) > N-methyl-2-pyrrolidone (NMP). Despite methanol’s superior solubility, its potential toxicity, coupled with the relatively lower effectiveness of other solvents compared to water, suggests that a co-solvency approach is not advantageous for ketamine HCl. We found that ketamine HCl solubility increased with medium acidity, with pH 3.5 being the optimal for further formulation studies. The impact of pharmaceutical surfactants on ketamine HCl solubility at an acidic pH was also evaluated. Surfactants tested included SDS, PEG 400, PVP, Tween 20, poloxamer 188, and lecithin. Notably, PEG 400 and PVP reduced solubility due to a salting-out effect, whereas Tween 80, lecithin, and poloxamer 188 slightly improved solubility through micelle formation. Among the surfactants tested, 1% SDS emerged as the most effective in enhancing ketamine HCl solubility. Conclusions: These outcomes highlight the potential of these solubilization strategies to address the solubility limitations of ketamine HCl, enabling the preparation of highly concentrated ketamine HCl formulations for intranasal delivery.